WO1990007525A1 - Keratoconjunctivitis cytotoxin and methods for its use and production - Google Patents
Keratoconjunctivitis cytotoxin and methods for its use and production Download PDFInfo
- Publication number
- WO1990007525A1 WO1990007525A1 PCT/US1990/000106 US9000106W WO9007525A1 WO 1990007525 A1 WO1990007525 A1 WO 1990007525A1 US 9000106 W US9000106 W US 9000106W WO 9007525 A1 WO9007525 A1 WO 9007525A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cytotoxin
- bovis
- vaccine
- peripheral blood
- bovine
- Prior art date
Links
- 231100000599 cytotoxic agent Toxicity 0.000 title claims abstract description 76
- 239000002619 cytotoxin Substances 0.000 title claims abstract description 76
- 101710112752 Cytotoxin Proteins 0.000 title claims abstract description 72
- 206010023332 keratitis Diseases 0.000 title claims abstract description 8
- 201000010666 keratoconjunctivitis Diseases 0.000 title claims abstract description 8
- 238000000034 method Methods 0.000 title claims description 17
- 238000004519 manufacturing process Methods 0.000 title description 4
- 210000000440 neutrophil Anatomy 0.000 claims abstract description 35
- 241000283690 Bos taurus Species 0.000 claims abstract description 32
- 229960005486 vaccine Drugs 0.000 claims abstract description 23
- 210000004027 cell Anatomy 0.000 claims abstract description 19
- 230000001472 cytotoxic effect Effects 0.000 claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 18
- 239000011886 peripheral blood Substances 0.000 claims abstract description 18
- 241000588622 Moraxella bovis Species 0.000 claims abstract description 16
- 230000002949 hemolytic effect Effects 0.000 claims abstract description 16
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical group CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000005018 casein Substances 0.000 claims abstract description 12
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000021240 caseins Nutrition 0.000 claims abstract description 12
- 241001465754 Metazoa Species 0.000 claims abstract description 11
- 230000000813 microbial effect Effects 0.000 claims abstract description 8
- 230000003301 hydrolyzing effect Effects 0.000 claims abstract description 7
- 208000015181 infectious disease Diseases 0.000 claims abstract description 6
- 150000003751 zinc Chemical class 0.000 claims abstract description 5
- 230000002458 infectious effect Effects 0.000 claims abstract description 4
- 231100000433 cytotoxic Toxicity 0.000 claims description 10
- 238000005349 anion exchange Methods 0.000 claims description 3
- 238000002255 vaccination Methods 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 abstract description 18
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 229920001817 Agar Polymers 0.000 description 16
- 239000008272 agar Substances 0.000 description 16
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical group OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 230000003013 cytotoxicity Effects 0.000 description 9
- 231100000135 cytotoxicity Toxicity 0.000 description 9
- 108010076119 Caseins Proteins 0.000 description 8
- 102000011632 Caseins Human genes 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 108010009004 proteose-peptone Proteins 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108010006464 Hemolysin Proteins Proteins 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 239000003228 hemolysin Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 3
- 229960001763 zinc sulfate Drugs 0.000 description 3
- 229910000368 zinc sulfate Inorganic materials 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 239000012506 Sephacryl® Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- KQHXBDOEECKORE-UHFFFAOYSA-L beryllium sulfate Chemical compound [Be+2].[O-]S([O-])(=O)=O KQHXBDOEECKORE-UHFFFAOYSA-L 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 244000144980 herd Species 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- VCJMYUPGQJHHFU-UHFFFAOYSA-N iron(3+);trinitrate Chemical compound [Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O VCJMYUPGQJHHFU-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- JRBJSXQPQWSCCF-UHFFFAOYSA-N 3,3'-Dimethoxybenzidine Chemical compound C1=C(N)C(OC)=CC(C=2C=C(OC)C(N)=CC=2)=C1 JRBJSXQPQWSCCF-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 208000031973 Conjunctivitis infective Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011026 Corneal lesion Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 239000004158 L-cystine Substances 0.000 description 1
- 235000019393 L-cystine Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000588628 Moraxella sp. Species 0.000 description 1
- 241000588656 Neisseriaceae Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 201000001028 acute contagious conjunctivitis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 229940103272 aluminum potassium sulfate Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003095 anti-phagocytic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229950001485 cocarboxylase Drugs 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 210000003683 corneal stroma Anatomy 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003560 epithelium corneal Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229940032296 ferric chloride Drugs 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000009998 heat setting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000009083 hemolysis by symbiont of host erythrocytes Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000001948 isotopic labelling Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229940046892 lead acetate Drugs 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- HEHQDWUWJVPREQ-XQJZMFRCSA-N lipid X Chemical compound CCCCCCCCCCC[C@@H](O)CC(=O)N[C@H]1[C@@H](OP(O)(O)=O)O[C@H](CO)[C@@H](O)[C@@H]1OC(=O)C[C@H](O)CCCCCCCCCCC HEHQDWUWJVPREQ-XQJZMFRCSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 231100001035 ocular change Toxicity 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229940066779 peptones Drugs 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012770 revaccination Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 229940013123 stannous chloride Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- YXVCLPJQTZXJLH-UHFFFAOYSA-N thiamine(1+) diphosphate chloride Chemical compound [Cl-].CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N YXVCLPJQTZXJLH-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000006150 trypticase soy agar Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
- C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- This invention relates to a keratoconjunctivitis cytotoxin, to methods for extracting and purifying the cytotoxin and to veterinary vaccines comprising the cytotoxin.
- IBK Infectious bovine keratoconjunctivitis
- Moraxella bovis Moraxella sp. are aerobic, gram-negative rods appearing in pairs of short chains. They belong to the Neisseriaceae family and are oxidase (+) and catalase (-) .
- IBK is highly contagious and can be transmitted rapidly throughout a herd. Acute to chronic inflammation of the eye occurs which impairs the animal's sight. This disease causes great financial loss in the cattle industry because it is a debilitating disease which affects cattle of all ages and breeds. *
- Moraxella bovis is considered to be the principal infectious agent associated with IBK.
- the earliest described ocular changes after inoculation of M ⁇ . bovis into the eyes of cattle include necrosis and sloughing of the corneal epithelium, and bacteria lying in pit-like defects on the surface of the epithelial cells.
- the margins of these pit ⁇ like defects conform closely to the shape of the associated bacterial cell, indicating that epithelial cell cytotoxicity may constitute an important pathogenic mechanism in the early stages of IBK.
- Macroscopically visible corneal ulcers may occur by 4 to 8 days after infection. At that time, the corneal stroma underlying the ulcerated area is infiltrated by bacteria and neutrophils. Many of the neutrophils and epithelial cells in the ulcerated areas appear necrotic.
- the toxin disclosed herein is useful for a preventative vaccine.
- This invention relates to a cytotoxin substantially free of intact microbial cells from Moraxella bovis which is toxic to bovine peripheral blood neutrophils and which lacks hemolytic activity.
- This cytotoxin is useful as a vaccine for protection of animals from infectious bovine keratoconjunctivitis.
- the cytotoxin is further characterized in that it is not capable of hydrolyzing casein, it is net negatively charged at a pH of 7.4 and by its ability to elute off of a DEAE exchange column with a 3ml gel bed under a salt gradient at a 0.2M t about a 0.3M salt concentration. Further, the cytotoxic activity to bovine peripheral blood neutrophils is sensitiv to zinc salt.
- the cytotoxin is prepared by clarifying and purifying culture filtrates of Moraxella bovis.
- ________ bovis which is cytotoxic to bovine peripheral blood neutrophils and which can be used as a vaccine against keratoconjunctivitis. Methods for purifying the cytotoxin are also disclosed. Extraction and Purification of the Cytotoxin
- Moraxella bovis strains useful in preparing the cytotoxin of the invention can be isolated from clinical cases of IBK or can be obtained from public sources.
- Publi sources include, for example, the American Type Culture Collection in Rockville, Maryland, U.S.A. (ATCC) where M. bovis strains are deposited under accession numbers 10900, 25576, 17947 and 17948. The most preferred strain is 5 " Tifto 1 strain, deposited with the ATCC on January 10, 1989 havin accession number 53854. The bacteria will grow on mos common bacterial culture media.
- M. bovis grown on McCoy's media (Grand Island Biologicals, Grand Island, New York or Flow Labs, Inglewood, California) supplemented with about 3% bovine serum albumin (BSA) and about 3% fetal calf serum yields filtrates with high levels of cytotoxic activity.
- BSA bovine serum albumin
- a minimal maxim be used which contains fewer exogenous proteins.
- Dialyzed GC media is a preferred minimal medium which yields good quantities of purified cytotoxin.
- Dialyzed GC media contains all components of GC media which is commercially available except that high molecular weight proteose peptone is substituted with proteose peptone which has been solubilized in water and dialyzed to remove high M peptones, typically those greater than about 14,000M .
- One liter of dialyzed GC media contains dialysate from 15g of powdered proteose peptone.
- Cytotoxin production is best if the bacteria is grown on agar plates rather than in liquid shake cultures.
- Agar plates or shake cultures are preferably incubated at a temperature of 37°C for about 18 to about 36 hours.
- the bacteria is harvested from the plates by washing the agar surface with an inorganic buffer having a molarity of about 0.01 to 0.05 and a pH of 7.4.
- the preferred buffer is Hepes and 200mM CaCl 2 .
- the buffer is added to the agar plates in a ratio of about 5ml:75cm 2 to about 15ml:75cm 2 of agar surface area.
- the culture filtrates are clarified by removing the solid materials by differential centrifugation, ultrafiltration or the like. Typically, the materials are centrifuged and the supernatant is then further purified by passing through a polycarbonate filter, preferably of about 0.22 ⁇ size.
- the crude filtrate is next precipitated by using standard techniques known in the field, such as the use of cold acetone or salts. Concentrations and other conditions vary with the salt chosen. Standard experimental strategies can be used to optimize selective precipitation for each salt. Selective precipitation using solutes is preferred. The solute most preferred is 70% ammonium sulfate.
- the filtrate may be centrifuged to collect the precipitate. Th precipitate is then collected and redissolved in a suitable buffer as described above.
- Th first protein peak is collected and diluted at about 1:2 to about 1:10, most preferably about 1:10, in a buffer solution, as described above.
- the preparation is then further purified using standard column chromatographic techniques which may include, for example, ion exchange chromatography, molecula filtration, electrophoresis, or isoelectric focusing.
- Standard columns generally recognized for use in purifying proteins are contemplated in purifying the cytotoxin of the present invention and many alternative columns are commercially available and known to those skilled in the art.
- the filtrate buffer solution is then placed on an anion exchange column such as those produced by Sigma Chemical Co., St. Louis, Missouri.
- the anion exchange column is preferably a DEAE-Sephadex, DEAE-Sephacryl or DEA cellulose column having about a 1ml to 10ml gel bed. A DEA column with about a 3ml gel bed is most preferred.
- the cytotoxin is eluted from the column through the use of a salt gradient.
- the cytotoxin solution is bound to the column, the column is then washed with buffer and then a salt gradient is passed through the column.
- the sal gradient may be of any range such that the range encompasse at least a 0.0M to 0.3M solution of a salt such as NaCl.
- the purified cytotoxin elutes off of a DEAE exchange column under a salt gradient at about 0.2M to about 0.3M NaCl concentration.
- eluate fraction may be individually tested to determine which fractions are cytotoxic to bovine peripheral blood neutrophils and which lack hemolytic activity. Characterization of the Cytotoxin
- the M ⁇ . bovis cytotoxin of this invention is substantially free of intact microbial cells which means that it has been derived from ML. bovis cultures and filtered or otherwise purified so that it is about preferably 95% to 100%, most preferably 100%, free of intact microbial cells.
- the M-_ bovis cytotoxin is cytotoxic to bovine peripheral blood neutrophils. This toxicity is measured by observing the release of chromium by the peripheral blood neutrophils upon subjection of the neutrophils to the cytotoxin pursuant to the methodology described by Miggiano et al. , Transpl. Proc.. 4_:231-237 (1972); Kurtz et al., Transfusion. .19.:398-403 (1979); and Carlson et al., Proc. Soc. Exp. Biol. Med. , 142:853-856 (1973).
- the preferred method is set forth in Example II below.
- the Mi. bovis cytotoxin is further characterized b its lack of hemolytic activity. Hemolytic activity can be assayed by methods known in the art such as that described by Bradley et al., J. Investi . Derm. ⁇ 78..206-209 (1982). The preferred method is that given in Example II below.
- the cytotoxin is not capable of hydrolyzing casein.
- the phrase "not capable of hydrolyzing casein” means that the cytotoxin, when placed in contact with a mil substrate, does not hydrolyze the casein and create clear zones in the media. Casein activity assays are described and well-known in the art as, for example, in U.S. Patent No. 4,675,176, which is incorporated by reference herein.
- the cytotoxin is further characterized in that it cytotoxicity to bovine peripheral blood neutrophils is inhibited by zinc salts, such as zinc sulfate. When the cytotoxin is placed into contact with a zinc salt at a fina concentration of 2mM its cytotoxicity to the neutrophils is inhibited.
- the cytotoxin has a molecular weight of about 42K based on polyacryla ide gel electrophoresis (PAGE) .
- PAGE polyacryla ide gel electrophoresis
- the cytotoxicity of the cytotoxin to bovine peripheral blood neutrophils is not inhibited when mixed with PMSF (40 ⁇ g/lml phenylmethane sulfonyl fluoride), pepstatin (0.7 ⁇ g/ml), TLC (50 ⁇ g/mi, l-l-chloro-3- [4-tosyl amido] -7-amino-2- heptanone-HCl) , phosphora idon (50 ⁇ g/ml) or leupeptin (0.5 ⁇ g/mi) either singly or together as a cocktail, all obtained from Boehringer Mannheim, Indianapolis, Indiana.
- PMSF 40 ⁇ g/lml phenylmethane sulfonyl fluoride
- the toxin is heat labile, being rapidly inactivated by heating at 56°C for over 15 minutes. It is net negatively charged molecule at a pH of 7.4.
- the cytotoxins described herein from Moraxella bovis further include those which are immunologically equivalent to the cytotoxins derived from M ⁇ . bovis culture filtrates. By immunologically equivalent, it is meant that the cytotoxin embraces those that are immunologically indistinct to the immune systems of cattle. Such cytotoxin would include proteins identical to the cytotoxins describe herein as well as those comprising minor modifications to the primary sequence of the protein, such as amino acid deletions, additions, substitutions or chemical modifications thereto (e.g., alkylation, reduction).
- the cytotoxins can be obtained from the cell cultures of M.
- bovis but can also be derived from chemical synthetic mean or recombinant genetic technology.
- To determine immunological equivalence one can use any number of standard immunological assays. The most convenient assay would involve competitive immunoassays wherein equivalence could be determined when antibodies against naturally secreted cytotoxin bind in about the same manner to about the same extent as the cytotoxin being assayed for equivalence.
- a vaccine prepared utilizing the purified cytotoxin or its immunogenic equivalents thereof can be pre ⁇ pared in vaccine dose form by well-known procedures.
- the vaccine can be administered intramuscularly or subcutaneously.
- the immunogen may be combined with a suitable carrier, for example, it may be administered in water, saline or buffered vehicles with or without various adjuvants or immunomodulating agents such as aluminum hydroxide, aluminum phosphate, aluminum potassium sulfate (alum) , beryllium sulfate, silica, kaolin, carbon, water-in- oil emulsions, oil-in-water emulsions, muramyl dipeptide, bacterial endotoxin, lipid X, Corvnebacterium parvum (Propi ⁇ nobacterium acnes) , Bordetella pertussis, poly- ribonucleotides, sodium alginate, lanolin, lysolecithin, vitamin A
- Such adjuvants are available commercially from various sources, for example, Merck Adjuvant 65 (Merck and Company, Irfc. , Rahway, N.J.). Other suitable adjuvants are Freund's Incom plete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, Michigan) .
- the proportion of immunogen and adjuvant can be varied over a broad range so long as both are present in effective amounts.
- aluminum hydroxide can be present in an amount of about 0.5% of the vaccine mixture (A1 2 0 3 basis).
- the concentration of the cytotoxin can range from about l ⁇ g to about 2,000 ⁇ g per bovine host.
- a preferable range is from about lOO ⁇ g to about l,000 ⁇ g per dose.
- a suitable dose size is about 1-lOml, preferably about 1.0ml.
- a dose for intramuscular injection for example, would comprise 1ml containing l.O g of immunogen in admixture with 0.5% aluminum hydroxide.
- Comparable dose forms can also be prepared for parenteral administration to calves, but the amount of immunogen per dose will be smaller, for example, about l ⁇ g to about 500 ⁇ g per dose.
- a regimen of between 1 and 4 doses can be used with the injections spaced out over a two- to six-week period.
- a two-dose regimen is used.
- the second dose of the vaccine then should be administered some weeks after the first dose, for example, about two to four weeks later.
- Animals that have been previously exposed to M. bovis or have received colostral antibodies from the mother may require booster injections.
- a two-dose regimen is considered preferable for the most effective immunization o the calves.
- Semiannual revaccination is recommended for breeding animals. Calves may be vaccinated at about 1-3 months after birth, again at four to six months, and yearly or preferably semi-annually thereafter.
- the vaccine may also be combined with other vac ⁇ cines for other diseases to produce multivalent vaccines. It may also be combined with other medicaments, for example antibiotics.
- a pharmaceutically effective amount of the vaccine can be employed with a pharmaceutically acceptable carrier or diluent understood to be useful for the vaccination of animals such as swine, cattle, sheep, goats, and other mammals.
- vaccines may be prepared according to meth- ods well-known to those skilled in the art as set forth, fo example, in I. Tizard, "An Introduction to Veterinary Immu ⁇ nology,” 2nd Ed (1982), which is incorporated herein by ref erence.
- the vaccine or the cytotoxin may be stored in lyophilized form. Though cytotoxic activity may be lost, the antigenic properties of the cytotoxin are maintained.
- M_-_ bovis The hemolytic isolate of M_-_ bovis for these experiments was obtained from a cow with IBK in Georgia (Tifton 1) .
- the bacterial isolate was maintained as lyophilized stock cultures. This isolate was positively identified as M. bovis using biochemical and morphologic criteria described in Smith and George, Am. J. Vet. Res. , 45:804-807 (1985) which is incorporated by reference herein.
- the sacs were sealed at both ends and washed thoroughly in distilled water. The sacs were then placed in a graduated cylinder with parafilm to seal the top. The cylinders were then placed in the refrigerator. Dialysis was allowed to occur for 24-36 hours in the cold.
- Hepes buffer (0.02M Hepes, lOOmg/l of calcium chloride) was pipetted into each of five, 15-ml screwcap pyrex tubes. Caps were screwed on each tube.
- Isovitalex bottles were obtained from Becton-Dickinson Microbiology Systems. These bottles contain ingredients important for growing Gonorrhea coccus. thus the reason for the name GC agar. Typically, these bottles contain the following ingredients: vitamin B 12 , L-glutamine, guanine HC1, PABA, cocarboxylase adenine, diphosphoparadine nucleotide, oxidized (coenzyme 1) , ferric nitrate, thiamine, L-cysteine HC1, and L-cystine.
- vitamins B 12 L-glutamine
- guanine HC1 guanine HC1
- PABA cocarboxylase adenine
- diphosphoparadine nucleotide diphosphoparadine nucleotide
- oxidized (coenzyme 1) ferric nitrate
- thiamine thiamine
- L-cysteine HC1 L-cystine
- Isovi ⁇ tale TM li•qui «d was combined with the lyophilized powder per the instructions. After the powder was dissolved, the fluid was aspirated. 7. The agar, cooled to 56°C, was removed from the waterbath. The entire contents of the IsovitalexTM bottle was added to the erlenmeyer flask. About 300m of agar were poured into each petri plate. The agar was allowed to harden before inoculation. 8. 2-10 "fried egg” type of M bovis colonies were inoculated into the sterile Hepes solution. A 5cc pipette was used to swish the fluid back and forth one or two times.
- the agar surface of each plate was flushed with 10ml of Hepes CaCl 2 (0.02M, lOOmg/1, pH 7.4) per 75cm 2 of the agar surface area.
- a sterile glass hockey stick was used to remove the bacterial growth.
- the harvested culture was pipetted into a 50-ml centrifuge tube. The tubes were centrifuged for 15 minutes at 3,000rpm. The supernatant was removed and filter-sterilized two times through a 0.22- micron polycarbonate filter (47mm diameter, Nucelopore, Inc., Pleasanton, California).
- the sterile filtrate then was diluted 1:2 in the low ionic strength Hepes buffer, as described above, and 40ml was pumped onto a 3ml gel bed DEAE column (DEAE Spectra gel M, Spectrum Medical Industries Inc. , Los Angeles,
- Bovine peripheral blood neutrophils were isolated by modification of methods described by Carlson et al., Proc. Soc. Exp. Biol. Med.. 142:853-856 (1973) and Chambers
- Heparinized blood 40ml was collected from the jugular vein of either of 2 normal adult donors. After collection, 10ml aliquots of blood were centrifuged (4°C, 500xg) for 15 minutes. After centrifugation, the plasma was aspirated and
- PBSS phosphate buffered saline solution
- the suspended cells then were layered over 4.0ml of lymphocyte separation media (density 1.077 to l.080g/ml, Litton Bionetics Inc., Kensington, Maryland) and the mixture was centrifuged for 25 minutes (4°C, 500xg) .
- lymphocyte separation media density 1.077 to l.080g/ml, Litton Bionetics Inc., Kensington, Maryland
- the cells were counted using a hemocyt ⁇ meter and the viability was determined by staining with 0.1% eosin dye in phosphate buffered saline. After washing, the cells were resuspended and adjusted to a final concentration of 2xl0 7 neutrophils/ml by the addition of
- the yield from each 40ml blood sample was approximately 5xl0 7 to 7xl0 7 cells, and was composed of 80% to 90% neutrophils. More than 90% of the cells were viable.
- Isotope labeling of the neutrophils was performed according to Kurtz et al., Transfusion, l :398-403 (1979).
- the purified neutrophil suspensions were incubated with 51 Cr labeled Na 2 Cr0 4 (100 ⁇ C/10 7 neutrophils, 37°C, 1 hour, ICN Inc. , Irvine, California) .
- the cells were rotated (Roto-Torque, Cole Palmer, Chicago, ⁇ L) .
- the cells were washed three times in cold PBSS and were finally resuspended in McCoy's to a final concentration of 1 x 10 6 neutrophils/ml before the radioactivity in 3 aliquots (0.5ml) of each cell suspension was counted (Autogamma Scintillation Spectrometer, Hewlett Packard, Palo Alto, California) .
- the cytotoxicity assays were performed by incubating 0.5ml of the labeled neutrophils at 37°C with 0.5ml of the preparation to be assayed (crude l_ _ bovis filtrates or partially purified fractions) for 30 minutes with gentle rotation.
- % Release cpm sample - cpm media controls x 2 x 100 (cpm neutrophils - cpm media controls)
- McCoy's media 25mM Hepes buffer, Gibco Inc., Grand Island, 15 New York
- Indicator substrate was 100ml phosphate buffer (0.6M, pH 6.0), 0.017ml of 30%H 2 O 2 , and 1.67mg/ml dianisidine (0.0167 g/lOOml buffer).
- Protein content was measured using the commercially available Lowry's test kit (Sigma Chemical Co. St. Louis, Missouri) .
- Table I sets forth the relative hemolytic and cytotoxic activity of fractions expressed in percent hemolysis or cytotoxicity.
- O.D. represents the optical density of the fraction at a wavelength of 280nm. The measurement is linearly related to the protein concentration of the fraction.
Abstract
This invention relates to a cytotoxin from Moraxella bovis substantially free of intact microbial cells, which is toxic to bovine peripheral blood neutrophils and which lacks hemolytic activity. This cytotoxin is useful as a vaccine for protection of animals from infectious bovine keratoconjunctivitis. The cytotoxin is further characterized in that it is not capable of hydrolyzing casein, it is net negatively charged at a pH of 7.4 and by its ability to elute off of a DEAE exchange column with a 3ml gel bed under a salt gradient at a 0.2M to about a 0.3M salt concentration. Further, the cytotoxic activity to bovine peripheral blood neutrophils is sensitive to zinc salts. Typically, the cytotoxin is prepared by clarifying and purifying culture filtrates of Moraxella bovis.
Description
KERATOCONJUNCTIVITIS CYTOTOXIN AND METHODS FOR ITS USE AND PRODUCTION
BACKGROUND OF THE INVENTION Field of the Invention This invention relates to a keratoconjunctivitis cytotoxin, to methods for extracting and purifying the cytotoxin and to veterinary vaccines comprising the cytotoxin.
Infectious bovine keratoconjunctivitis (IBK) is a serious disease of the eyes of cattle commonly known as pinkeye. It is caused by the bacteria Moraxella bovis. Moraxella sp. are aerobic, gram-negative rods appearing in pairs of short chains. They belong to the Neisseriaceae family and are oxidase (+) and catalase (-) . IBK is highly contagious and can be transmitted rapidly throughout a herd. Acute to chronic inflammation of the eye occurs which impairs the animal's sight. This disease causes great financial loss in the cattle industry because it is a debilitating disease which affects cattle of all ages and breeds. *
Although IBK was first described a century ago, the pathogenesis of the disease is not yet understood. Moraxella bovis is considered to be the principal infectious agent associated with IBK. The earliest described ocular changes after inoculation of M^. bovis into the eyes of cattle include necrosis and sloughing of the corneal epithelium, and bacteria lying in pit-like defects on the surface of the epithelial cells. The margins of these pit¬ like defects conform closely to the shape of the associated bacterial cell, indicating that epithelial cell cytotoxicity may constitute an important pathogenic mechanism in the early stages of IBK.
Macroscopically visible corneal ulcers may occur by 4 to 8 days after infection. At that time, the corneal stroma underlying the ulcerated area is infiltrated by bacteria and neutrophils. Many of the neutrophils and epithelial cells in the ulcerated areas appear necrotic.
The contribution of these inflammatory cells to the corneal lesions of IBK is unclear; however, studies have indicated that degenerating polymorphonuclear leukocytes release enzymes into the cornea which may increase the size of ulcers and retard healing. Thus, a toxin effect of M^. bovi upon neutrophils could result in the release of endogenous mediators capable of increasing corneal destruction. Cytotoxicity by ________ bovis also would confer antiphagocytic effects upon bacterium. Although previous studies have shown that I . bovis is toxic to bovine monocytes .in vitro, the cytotoxic effect of the bacterium on neutrophils was previously unknown.
Treatment of an animal infected with IBK is difficult and impractical as current treatment methods are not generally cost effective. Further, treatment is complicated if the disease occurs in a range herd. Thus, preventative treatment through the use of a vaccine would b highly desirable. The toxin disclosed herein is useful for a preventative vaccine.
SUMMARY OF THE INVENTION This invention relates to a cytotoxin substantially free of intact microbial cells from Moraxella bovis which is toxic to bovine peripheral blood neutrophils and which lacks hemolytic activity. This cytotoxin is useful as a vaccine for protection of animals from infectious bovine keratoconjunctivitis. The cytotoxin is further characterized in that it is not capable of hydrolyzing casein, it is net negatively charged at a pH of
7.4 and by its ability to elute off of a DEAE exchange column with a 3ml gel bed under a salt gradient at a 0.2M t about a 0.3M salt concentration. Further, the cytotoxic activity to bovine peripheral blood neutrophils is sensitiv to zinc salt. Typically, the cytotoxin is prepared by clarifying and purifying culture filtrates of Moraxella bovis.
DETAILED DESCRIPTION This invention relates to a cytotoxin derived fro
________ bovis which is cytotoxic to bovine peripheral blood neutrophils and which can be used as a vaccine against keratoconjunctivitis. Methods for purifying the cytotoxin are also disclosed. Extraction and Purification of the Cytotoxin
Moraxella bovis strains useful in preparing the cytotoxin of the invention can be isolated from clinical cases of IBK or can be obtained from public sources. Publi sources include, for example, the American Type Culture Collection in Rockville, Maryland, U.S.A. (ATCC) where M. bovis strains are deposited under accession numbers 10900, 25576, 17947 and 17948. The most preferred strain is5" Tifto 1 strain, deposited with the ATCC on January 10, 1989 havin accession number 53854. The bacteria will grow on mos common bacterial culture media.
M. bovis grown on McCoy's media (Grand Island Biologicals, Grand Island, New York or Flow Labs, Inglewood, California) supplemented with about 3% bovine serum albumin (BSA) and about 3% fetal calf serum yields filtrates with high levels of cytotoxic activity. However, for cytotoxin purification purposes, it is preferred that a minimal mediu be used which contains fewer exogenous proteins. Dialyzed GC media is a preferred minimal medium which yields good quantities of purified cytotoxin. Dialyzed GC media
contains all components of GC media which is commercially available except that high molecular weight proteose peptone is substituted with proteose peptone which has been solubilized in water and dialyzed to remove high M peptones, typically those greater than about 14,000M . One liter of dialyzed GC media contains dialysate from 15g of powdered proteose peptone.
Cytotoxin production is best if the bacteria is grown on agar plates rather than in liquid shake cultures. Agar plates or shake cultures are preferably incubated at a temperature of 37°C for about 18 to about 36 hours.
After incubation, the bacteria is harvested from the plates by washing the agar surface with an inorganic buffer having a molarity of about 0.01 to 0.05 and a pH of 7.4. The preferred buffer is Hepes and 200mM CaCl2.
Preferably, the buffer is added to the agar plates in a ratio of about 5ml:75cm2 to about 15ml:75cm2 of agar surface area.
The culture filtrates are clarified by removing the solid materials by differential centrifugation, ultrafiltration or the like. Typically, the materials are centrifuged and the supernatant is then further purified by passing through a polycarbonate filter, preferably of about 0.22μ size. The crude filtrate is next precipitated by using standard techniques known in the field, such as the use of cold acetone or salts. Concentrations and other conditions vary with the salt chosen. Standard experimental strategies can be used to optimize selective precipitation for each salt. Selective precipitation using solutes is preferred. The solute most preferred is 70% ammonium sulfate. The filtrate may be centrifuged to collect the precipitate. Th precipitate is then collected and redissolved in a suitable buffer as described above. After the precipitation of the
cytotoxin and resuspension in buffer solution, it has been found to be most advantageous to pass the preparation through a molecular filtration device such as a Bio Gel PD- 10 column (Bio-Rad Laboratories, Richmond, California) . Th first protein peak is collected and diluted at about 1:2 to about 1:10, most preferably about 1:10, in a buffer solution, as described above.
The preparation is then further purified using standard column chromatographic techniques which may include, for example, ion exchange chromatography, molecula filtration, electrophoresis, or isoelectric focusing. Standard columns generally recognized for use in purifying proteins are contemplated in purifying the cytotoxin of the present invention and many alternative columns are commercially available and known to those skilled in the art.
The filtrate buffer solution is then placed on an anion exchange column such as those produced by Sigma Chemical Co., St. Louis, Missouri. The anion exchange column is preferably a DEAE-Sephadex, DEAE-Sephacryl or DEA cellulose column having about a 1ml to 10ml gel bed. A DEA column with about a 3ml gel bed is most preferred. The cytotoxin is eluted from the column through the use of a salt gradient. Preferably, the cytotoxin solution is bound to the column, the column is then washed with buffer and then a salt gradient is passed through the column. The sal gradient may be of any range such that the range encompasse at least a 0.0M to 0.3M solution of a salt such as NaCl. The purified cytotoxin elutes off of a DEAE exchange column under a salt gradient at about 0.2M to about 0.3M NaCl concentration.
Using the method described below, eluate fraction may be individually tested to determine which fractions are
cytotoxic to bovine peripheral blood neutrophils and which lack hemolytic activity. Characterization of the Cytotoxin
The M^. bovis cytotoxin of this invention is substantially free of intact microbial cells which means that it has been derived from ML. bovis cultures and filtered or otherwise purified so that it is about preferably 95% to 100%, most preferably 100%, free of intact microbial cells. The M-_ bovis cytotoxin is cytotoxic to bovine peripheral blood neutrophils. This toxicity is measured by observing the release of chromium by the peripheral blood neutrophils upon subjection of the neutrophils to the cytotoxin pursuant to the methodology described by Miggiano et al. , Transpl. Proc.. 4_:231-237 (1972); Kurtz et al., Transfusion. .19.:398-403 (1979); and Carlson et al., Proc. Soc. Exp. Biol. Med. , 142:853-856 (1973). The preferred method is set forth in Example II below.
The Mi. bovis cytotoxin is further characterized b its lack of hemolytic activity. Hemolytic activity can be assayed by methods known in the art such as that described by Bradley et al., J. Investi . Derm. ■ 78..206-209 (1982). The preferred method is that given in Example II below.
The cytotoxin is not capable of hydrolyzing casein. The phrase "not capable of hydrolyzing casein" means that the cytotoxin, when placed in contact with a mil substrate, does not hydrolyze the casein and create clear zones in the media. Casein activity assays are described and well-known in the art as, for example, in U.S. Patent No. 4,675,176, which is incorporated by reference herein. The cytotoxin is further characterized in that it cytotoxicity to bovine peripheral blood neutrophils is inhibited by zinc salts, such as zinc sulfate. When the cytotoxin is placed into contact with a zinc salt at a fina
concentration of 2mM its cytotoxicity to the neutrophils is inhibited.
The cytotoxin has a molecular weight of about 42K based on polyacryla ide gel electrophoresis (PAGE) . The cytotoxicity of the cytotoxin to bovine peripheral blood neutrophils is not inhibited when mixed with PMSF (40μg/lml phenylmethane sulfonyl fluoride), pepstatin (0.7μg/ml), TLC (50μg/mi, l-l-chloro-3- [4-tosyl amido] -7-amino-2- heptanone-HCl) , phosphora idon (50μg/ml) or leupeptin (0.5μg/mi) either singly or together as a cocktail, all obtained from Boehringer Mannheim, Indianapolis, Indiana.
The toxin is heat labile, being rapidly inactivated by heating at 56°C for over 15 minutes. It is net negatively charged molecule at a pH of 7.4. The cytotoxins described herein from Moraxella bovis further include those which are immunologically equivalent to the cytotoxins derived from M^. bovis culture filtrates. By immunologically equivalent, it is meant that the cytotoxin embraces those that are immunologically indistinct to the immune systems of cattle. Such cytotoxin would include proteins identical to the cytotoxins describe herein as well as those comprising minor modifications to the primary sequence of the protein, such as amino acid deletions, additions, substitutions or chemical modifications thereto (e.g., alkylation, reduction). The cytotoxins can be obtained from the cell cultures of M. bovis. but can also be derived from chemical synthetic mean or recombinant genetic technology. To determine immunological equivalence, one can use any number of standard immunological assays. The most convenient assay would involve competitive immunoassays wherein equivalence could be determined when antibodies against naturally secreted cytotoxin bind in about the same manner to about
the same extent as the cytotoxin being assayed for equivalence.
Vaccines Using the Cytotoxin
A vaccine prepared utilizing the purified cytotoxin or its immunogenic equivalents thereof can be pre¬ pared in vaccine dose form by well-known procedures. The vaccine can be administered intramuscularly or subcutaneously. For parenteral administration, such as subcutaneous injection, the immunogen may be combined with a suitable carrier, for example, it may be administered in water, saline or buffered vehicles with or without various adjuvants or immunomodulating agents such as aluminum hydroxide, aluminum phosphate, aluminum potassium sulfate (alum) , beryllium sulfate, silica, kaolin, carbon, water-in- oil emulsions, oil-in-water emulsions, muramyl dipeptide, bacterial endotoxin, lipid X, Corvnebacterium parvum (Propiσnobacterium acnes) , Bordetella pertussis, poly- ribonucleotides, sodium alginate, lanolin, lysolecithin, vitamin A, saponin, liposomes, levamisole, DEAE-dextran, blocked copolymers or other synthetic adjuvants. Such adjuvants are available commercially from various sources, for example, Merck Adjuvant 65 (Merck and Company, Irfc. , Rahway, N.J.). Other suitable adjuvants are Freund's Incom plete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, Michigan) .
The proportion of immunogen and adjuvant can be varied over a broad range so long as both are present in effective amounts. For example, aluminum hydroxide can be present in an amount of about 0.5% of the vaccine mixture (A1203 basis). On a per-dose basis, the concentration of the cytotoxin can range from about lμg to about 2,000μg per bovine host. A preferable range is from about lOOμg to about l,000μg per dose. A suitable dose size is about 1-lOml, preferably about 1.0ml. Accordingly, a dose for
intramuscular injection, for example, would comprise 1ml containing l.O g of immunogen in admixture with 0.5% aluminum hydroxide. Comparable dose forms can also be prepared for parenteral administration to calves, but the amount of immunogen per dose will be smaller, for example, about lμg to about 500μg per dose.
For the initial vaccination of immunologically naive cows, a regimen of between 1 and 4 doses can be used with the injections spaced out over a two- to six-week period. Typically, a two-dose regimen is used. The second dose of the vaccine then should be administered some weeks after the first dose, for example, about two to four weeks later. Animals that have been previously exposed to M. bovis or have received colostral antibodies from the mother may require booster injections. A two-dose regimen is considered preferable for the most effective immunization o the calves. Semiannual revaccination is recommended for breeding animals. Calves may be vaccinated at about 1-3 months after birth, again at four to six months, and yearly or preferably semi-annually thereafter.
The vaccine may also be combined with other vac¬ cines for other diseases to produce multivalent vaccines. It may also be combined with other medicaments, for example antibiotics. A pharmaceutically effective amount of the vaccine can be employed with a pharmaceutically acceptable carrier or diluent understood to be useful for the vaccination of animals such as swine, cattle, sheep, goats, and other mammals.
Other vaccines may be prepared according to meth- ods well-known to those skilled in the art as set forth, fo example, in I. Tizard, "An Introduction to Veterinary Immu¬ nology," 2nd Ed (1982), which is incorporated herein by ref erence.
The vaccine or the cytotoxin may be stored in lyophilized form. Though cytotoxic activity may be lost, the antigenic properties of the cytotoxin are maintained.
EXAMPLES
I. CULTURING M. BOVIS AND CYTOTOXIN PRODUCTION A. Bacterial Isolates
The hemolytic isolate of M_-_ bovis for these experiments was obtained from a cow with IBK in Georgia (Tifton 1) . The bacterial isolate was maintained as lyophilized stock cultures. This isolate was positively identified as M. bovis using biochemical and morphologic criteria described in Smith and George, Am. J. Vet. Res. , 45:804-807 (1985) which is incorporated by reference herein. B. Preparation of dialyzed GC Media
1. 15g of proteose peptone #3 were solubilized in 50ml of distilled water 24 hours prior to making the media.
2. Six strips of dialysis tubing (6MW to 14,000MW), 40cm to 45cm long were cut and moistened in distilled water. Each was filled with 12ml of the solubilized proteose peptone. p
3. The sacs were sealed at both ends and washed thoroughly in distilled water. The sacs were then placed in a graduated cylinder with parafilm to seal the top. The cylinders were then placed in the refrigerator. Dialysis was allowed to occur for 24-36 hours in the cold.
4. After dialysis, the sacs were removed. Distilled water was added to the dialysate to give a final volume of 1 liter. Sodium chloride NaCl (5g) corn starch
(lg) , potassium phosphate (dibasic, 4g) , potassium phosphate (monobasic, lg) , and agar (lOg) were added in a 2-liter erlenmeyer flask. The flask was placed on a hot plate with constant stirring set at a heat setting of 6 until the agar
was melted — about 15-20 minutes. The flask was equipped with a cotton, gauze plug and aluminum foil stopper and was autoclaved for 18 minutes, no dry, liquid cycle. After autoclaving the media was put in a 56°C waterbath until the temperature was equilibrated.
5. 5ml of Hepes buffer (0.02M Hepes, lOOmg/l of calcium chloride) was pipetted into each of five, 15-ml screwcap pyrex tubes. Caps were screwed on each tube.
6. Isovitalex bottles were obtained from Becton-Dickinson Microbiology Systems. These bottles contain ingredients important for growing Gonorrhea coccus. thus the reason for the name GC agar. Typically, these bottles contain the following ingredients: vitamin B12, L-glutamine, guanine HC1, PABA, cocarboxylase adenine, diphosphoparadine nucleotide, oxidized (coenzyme 1) , ferric nitrate, thiamine, L-cysteine HC1, and L-cystine. The
Isovi ■tale TM li•qui«d was combined with the lyophilized powder per the instructions. After the powder was dissolved, the fluid was aspirated. 7. The agar, cooled to 56°C, was removed from the waterbath. The entire contents of the Isovitalex™ bottle was added to the erlenmeyer flask. About 300m of agar were poured into each petri plate. The agar was allowed to harden before inoculation. 8. 2-10 "fried egg" type of M bovis colonies were inoculated into the sterile Hepes solution. A 5cc pipette was used to swish the fluid back and forth one or two times. 2-5ml of the inoculated buffer was pipetted onto each agar surface. The inoculum was spread onto this agar surface using a sterile glass hockey stick. The plates were wrapped and incubated for 24 hours at 37°C. The plates were
ready for harvest and were all checked for purity of growth. C. Purification of the Cytotoxin
1. The agar surface of each plate was flushed with 10ml of Hepes CaCl2 (0.02M, lOOmg/1, pH 7.4) per 75cm2 of the agar surface area. A sterile glass hockey stick was used to remove the bacterial growth. The harvested culture was pipetted into a 50-ml centrifuge tube. The tubes were centrifuged for 15 minutes at 3,000rpm. The supernatant was removed and filter-sterilized two times through a 0.22- micron polycarbonate filter (47mm diameter, Nucelopore, Inc., Pleasanton, California).
2. The sterile filtrate then was diluted 1:2 in the low ionic strength Hepes buffer, as described above, and 40ml was pumped onto a 3ml gel bed DEAE column (DEAE Spectra gel M, Spectrum Medical Industries Inc. , Los Angeles,
California) (l.Oml/minute) . After the toxin filtrate was applied, the column was washed in 30ml of buffer. The proteins were eluted from the column differentially by application of 30ml of Hepes buffer containing 0.1ml of NaCl, followed by a salt gradient (0.1M to 0.3M, 30ml in Hepes buffer) .
3. The eluate was removed in 3ml fractions and each fraction was tested for cytotoxic and hemolytic activity as described below. He olysin eluted at approximately 0.18M NaCl concentration. Cytotoxin eluted at 0.22M NaCl concentration. Fractions containing the cytotoxin consistently showed a single SDS polyacrylamide gel electrophoresis protein band with an apparent molecular weight of 42KD. The fractions containing the hemolysin contained a large number of proteins.
II. CHARACTERISTICS OF THE CYTOTOXIN
A. Tests for Cytotoxicity and Hemolytic Activity
Cytotoxicity tests were done by challenging bovine ° peripheral blood neutrophils with solutions containing the
5 cytotoxin as described below: • 1. Neutrophil Preparation
Bovine peripheral blood neutrophils were isolated by modification of methods described by Carlson et al., Proc. Soc. Exp. Biol. Med.. 142:853-856 (1973) and Chambers
10 et al., Vet. Immunopath.. J5:197-202 (1983). Heparinized blood (40ml) was collected from the jugular vein of either of 2 normal adult donors. After collection, 10ml aliquots of blood were centrifuged (4°C, 500xg) for 15 minutes. After centrifugation, the plasma was aspirated and
15 discarded. Then, 2ml of the buffy coat and topmost layers of the packed erythrocytes was removed from each tube, and pooled. The erythrocytes in the pooled sample were lysed osmotically by the addition of 40ml of cold distilled water. The cell suspension was gently agitated for 20 seconds, and
20 then hemolysis was stopped by addition of 20ml of cold hypertonic phosphate buffered saline solution (2.7% NaCl, 0.007M phosphate buffer, pH 6.8). The cell suspension then was centrifuged for 10 minutes (4°C, 175xg) . After centrifugation, the pellet was resuspended in 8ml of
25 phosphate buffered saline solution (PBSS, 0.007M, pH 6.8, 0.9% NaCl) . The suspended cells then were layered over 4.0ml of lymphocyte separation media (density 1.077 to l.080g/ml, Litton Bionetics Inc., Kensington, Maryland) and the mixture was centrifuged for 25 minutes (4°C, 500xg) .
30 After centrifugation, the supernatant was discarded, and the cell pellet was washed three times in cold PBSS. Just prior to the final wash, the cells were counted using a hemocytσmeter and the viability was determined by staining with 0.1% eosin dye in phosphate buffered saline. After
washing, the cells were resuspended and adjusted to a final concentration of 2xl07 neutrophils/ml by the addition of
PBSS. The yield from each 40ml blood sample was approximately 5xl07 to 7xl07 cells, and was composed of 80% to 90% neutrophils. More than 90% of the cells were viable.
Human neutrophils were purified by the Ficoll-Hypaque and dextran density gradient sedimentation method as described by Boyum, Scand. J. Clin. Lab. Invest.. 21 Supp.97:77-89
(1968) . 2. Chromium Release Studies as an Indication of
Cytotoxicity
Isotope labeling of the neutrophils was performed according to Kurtz et al., Transfusion, l :398-403 (1979). The purified neutrophil suspensions were incubated with 51Cr labeled Na2Cr04 (100 μC/107 neutrophils, 37°C, 1 hour, ICN Inc. , Irvine, California) . During incubation, the cells were rotated (Roto-Torque, Cole Palmer, Chicago, ΪL) . After incubation, the cells were washed three times in cold PBSS and were finally resuspended in McCoy's to a final concentration of 1 x 106 neutrophils/ml before the radioactivity in 3 aliquots (0.5ml) of each cell suspension was counted (Autogamma Scintillation Spectrometer, Hewlett Packard, Palo Alto, California) . The cytotoxicity assays were performed by incubating 0.5ml of the labeled neutrophils at 37°C with 0.5ml of the preparation to be assayed (crude l_ _ bovis filtrates or partially purified fractions) for 30 minutes with gentle rotation. When fractions were taken from the DEAE exchange column as described in Example I.C.3. above, 0.5ml of each 3ml fraction was promptly incubated with the neutrophils after elution. Incubation of the labeled cells in McCoy's served as a negative control. After incubation, the cells were sedimented by centrifugation (200xg, 4°C) for 10 minutes, and the radioactivity in 0.5ml of the
supernatant was measured. Data reflected the mean of duplicate determinations, and were recorded as a percent of 51Cr release, using a modification of a recommended expression (Miggiano et al., Transpl. Proc.. 4.:231-237 5 (1972)):
*
% Release = cpm sample - cpm media controls x 2 x 100 (cpm neutrophils - cpm media controls)
10 Table I below shows the cytotoxic activities of fractions taken off the DEAE column.
3. Hemolysin Activity
Hemolysin assays were performed in phenol-red free
McCoy's media (25mM Hepes buffer, Gibco Inc., Grand Island, 15 New York) using the method described by Ostle et al., Am. J.
Vet. Res. , 4_5:1848-1851 (1984). Hemolysin release was determined by the following protocol: a. Filtrate or eluate fractions from Example
I.C.3. above to be tested were obtained. 20 b. A 0.5ml aliquot of the filtrate or eluate fraction was mixed with 0.01 ml of 3x washed packed erythrocytes (RBC) washed 3x in McCoy's media. The suspending buffer was sterile 0.017M PBSS in NaCl (pH7.,.4) with 2.0 mM CaCl2 making the final RBC concentration 2%. 25 When eluate fractions were taken from the DEAE column, each fraction was promptly incubated with the erythrocytes. c. Controls were prepared which consisted of the washed RBC's and 0.5ml of sterile McCoy's medium. d. All samples were incubated at 37°C for 8 30 hours. e. The samples were spun immediately, and the supernatant was tested for peroxidase activity. f. Peroxidase activity was tested by adding 3.0ml of reaction mixture to 0.20ml of supernatant, and
35 measuring the change in O.D. (460nm) for one minute.
(Settings on recorder were range = 1000, speed = lem/min) .
The change in O.D. per minute was multiplied by 2.65 to determine the peroxidase units. g. Indicator substrate was 100ml phosphate buffer (0.6M, pH 6.0), 0.017ml of 30%H2O2, and 1.67mg/ml dianisidine (0.0167 g/lOOml buffer). h. Protein content was measured using the commercially available Lowry's test kit (Sigma Chemical Co. St. Louis, Missouri) .
Table I sets forth the relative hemolytic and cytotoxic activity of fractions expressed in percent hemolysis or cytotoxicity. The term O.D. represents the optical density of the fraction at a wavelength of 280nm. The measurement is linearly related to the protein concentration of the fraction. Table I
Solutions of 2mM of lead acetate, ferric chloride, zinc sulfate, stannous chloride or aluminum hydroxide in McCoy's media were added to sterile filtrates and incubated 5 for 30 minutes before testing for their effect on the * cytotoxic and hemolytic activities.
M. bovis culture filtrates were then tested for cytotoxic activity against bovine peripheral blood neutrophils and for hemolytic activity by the tests 10 described above.
Zinc sulfate completely inhibited the cytotoxic activity of the filtrates, but had no effect upon the hemolytic activity. None of the other solutions affected the cytotoxicity of the filtrates. 15 Casein Hydrolysis Study
This test was done to determine whether the cytotoxin could hydrolyze protein, casein in particular. Protease activity of the cytotoxin was measured in Trypticase Soy Agar plates containing 0.5% autoclaved skim 20 milk. Ten microliters of the cytotoxin were added to 3mm wells within the agar. The plates were examined for zones of milk proteolysis after 24 hours. No clear zones occurred around the cytotoxin wells indicating that the cytotoxin was unable to hydrolyze casein. 25 D. Vaccine Preparation and Administration
1. Precipitate crude ML. bovis filtrate with 70% ammonium sulfate for 4 hours.
2. Centrifuge pellet at 20,000xg for 1 hour.
3. Resuspend pellet in Hepes buffer (0.02M, pH 30 7.4).
4. Pass through Bio-Gel PD-10 column, collect first protein peak and dilute 1:10 in Hepes buffer.
5. Absorb to DEAE Sephacryl® column.
6. Elute with 0.3M NaCl in Hepes buffer.
7. Mix eluate 1:1 with adjuvant.
8. Inject lml of the mixture subcutaneously into an adult cow.
Claims
WHAT IS CLAIMED IS:
* 1. A cytotoxin from Moraxella bovis
5 substantially free of intact microbial cells, and possessing
* the following characteristics:
(a) cytotoxic to bovine peripheral blood neutrophils; and
(b) lacks hemolytic activity. 10
2. The cytotoxin of claim 1, wherein the cytotoxin is not capable of hydrolyzing casein.
3. The cytotoxin of claim 1, wherein the
15 cytotoxic activity to bovine peripheral blood neutrophils is sensitive to zinc salts.
4. The cytotoxin of claim 1, wherein the cytotoxin is net negatively charged at a pH of 7.4.
20
5. The cytotoxin of claim 1, further characterized by its ability to elute off of a DEAE exchange column with a 3ml gel bed under a salt gradient at a 0.2M to about a 0.3M salt concentration.
25
6. A vaccine for protection of animals from Moraxella bovis comprising a cytotoxin from M-_ bovis substantially free of intact microbial cells, which is cytotoxic to bovine peripheral blood neutrophils and which
30 lacks hemolytic activity.
7. The vaccine of claim 6, wherein the cytotoxin is not capable of hydrolyzing casein.
8. The vaccine of claim 6, wherein the cytotoxin is further characterized by its ability to elute off of a DEAE column under a salt gradient at a 0.2M to about a 0.3M salt concentration.
9. A method for protecting animals from infection of M_s_ bovis which comprises the vaccination of the animals with a vaccine comprising a cytotoxin substantially free of intact microbial cells derived from j_ bovis which is cytotoxic to bovine peripheral blood neutrophils and which lacks hemolytic activity.
10. The method of claim 9, wherein the cytotoxin is further characterized by its ability to elute off of an anion exchange column under a salt gradient at a 0.2M to about a 0.3M salt concentration.
11. A vaccine for protection of animals from infectious bovine keratoconjunctivitis comprising a cytotoxin substantially free of intact microbial cells the cytotoxin from M-_ bovis and characterized by:
(a) its ability to elute off of a DEAE exchange column having a 3ml gel bed at about a 0.2M to about 0.3M salt concentration; and (b) upon elution from the column is cytotoxic to bovine peripheral blood neutrophils and lacks hemolytic activity.
12. The vaccine of claim 11, wherein the cytotoxin is not capable of hydrolyzing casein.
13. The vaccine of claim 11, wherein the cytotoxin is net negatively charged at a pH of 7.4.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29423989A | 1989-01-06 | 1989-01-06 | |
US294,239 | 1989-01-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1990007525A1 true WO1990007525A1 (en) | 1990-07-12 |
Family
ID=23132503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1990/000106 WO1990007525A1 (en) | 1989-01-06 | 1990-01-05 | Keratoconjunctivitis cytotoxin and methods for its use and production |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU5088690A (en) |
WO (1) | WO1990007525A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996012502A1 (en) * | 1994-10-25 | 1996-05-02 | Kansas State University Research Foundation | Method of culturing m. bovis in low available iron media and production of infectious bovine keratoconjunctivitis vaccine therefrom |
WO2001016172A1 (en) * | 1999-08-31 | 2001-03-08 | Commonwealth Scientific And Industrial Research Organisation | Vaccine antigens of moraxella |
WO2002102408A1 (en) * | 2001-06-19 | 2002-12-27 | The Regents Of The University Of California | Moraxella bovis cytotoxin, cytotoxin gene, antibodies and vaccines for prevention and treatment of moraxella bovis infections |
US9668677B2 (en) | 2004-07-13 | 2017-06-06 | Dexcom, Inc. | Analyte sensor |
US10524703B2 (en) | 2004-07-13 | 2020-01-07 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10610137B2 (en) | 2005-03-10 | 2020-04-07 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986006635A1 (en) * | 1985-05-15 | 1986-11-20 | Biotechnology Australia Pty. Ltd. | Oral vaccines |
-
1990
- 1990-01-05 AU AU50886/90A patent/AU5088690A/en not_active Abandoned
- 1990-01-05 WO PCT/US1990/000106 patent/WO1990007525A1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986006635A1 (en) * | 1985-05-15 | 1986-11-20 | Biotechnology Australia Pty. Ltd. | Oral vaccines |
Non-Patent Citations (5)
Title |
---|
AMERICAN JOURNAL OF VETERINARY RESEARCH, Volume 36(3), issued March 1975, HUGHES et al.: "Experimentally Induced Infectious Bovine Keratoconjuctivitis; Relationship of Vaccination Schedule to Protection Against Exposure with Homologous Moraella bouis Culture", pages 263-265. See the Summary and the last paragraph. * |
AMERICAN JOURNAL OF VETERINARY RESEARCH, Volume 50(1), issued January 1989, KAGONYERA et al.: "Effects of Moraxella bovis and Culture filtrates on 51 Cr-labeled Bovine Neutrophils", pages 18-21. See the Discussion pages 20-21. * |
AMERICAN JOURNAL OF VETERINARY RESEARCH, Volume 51(2), issued February 1990, HOIEN-DALEN et al.: "Comparative Characterization of the Leukocidic and Hemolytic Activity of Moraxella bocis", pages 191-196. See entire document. * |
CANADIAN JOURNAL OF COMPARATIVE MEDICINE, Volume 37, issued January 1973, PUGH et al.: "The Pathophysiological Effects of Moraxella bovis Toxins on Cattle, Mice, an Guinea Pigs", pages 70-78. See the Abstract and pages 76-77. * |
CONFERENCE OF RESEARCH WORKS IN ANIMAL DISEASE, Abstract Number 49, Published 1988, HOIEN-DALEN et al.: "Partial Characterization of a Moraxella bovis Leukocidin and Comparison to the M. bovis Hemolysin", page 9. See the entire abstract. * |
Cited By (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996012502A1 (en) * | 1994-10-25 | 1996-05-02 | Kansas State University Research Foundation | Method of culturing m. bovis in low available iron media and production of infectious bovine keratoconjunctivitis vaccine therefrom |
WO2001016172A1 (en) * | 1999-08-31 | 2001-03-08 | Commonwealth Scientific And Industrial Research Organisation | Vaccine antigens of moraxella |
US7018639B1 (en) | 1999-08-31 | 2006-03-28 | Commonwealth Scientific And Industrial Research Organisation | Vaccine antigens of Moraxella |
WO2002102408A1 (en) * | 2001-06-19 | 2002-12-27 | The Regents Of The University Of California | Moraxella bovis cytotoxin, cytotoxin gene, antibodies and vaccines for prevention and treatment of moraxella bovis infections |
US7220421B2 (en) * | 2001-06-19 | 2007-05-22 | The Regents Of The University Of California | Moraxella bovis cytotoxin, cytotoxin gene, antibodies and vaccines for prevention and treatment of Moraxella bovis infections |
US11026605B1 (en) | 2004-07-13 | 2021-06-08 | Dexcom, Inc. | Analyte sensor |
US10993642B2 (en) | 2004-07-13 | 2021-05-04 | Dexcom, Inc. | Analyte sensor |
US11883164B2 (en) | 2004-07-13 | 2024-01-30 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US11064917B2 (en) | 2004-07-13 | 2021-07-20 | Dexcom, Inc. | Analyte sensor |
US11045120B2 (en) | 2004-07-13 | 2021-06-29 | Dexcom, Inc. | Analyte sensor |
US9668677B2 (en) | 2004-07-13 | 2017-06-06 | Dexcom, Inc. | Analyte sensor |
US10709363B2 (en) | 2004-07-13 | 2020-07-14 | Dexcom, Inc. | Analyte sensor |
US10918315B2 (en) | 2004-07-13 | 2021-02-16 | Dexcom, Inc. | Analyte sensor |
US10709362B2 (en) | 2004-07-13 | 2020-07-14 | Dexcom, Inc. | Analyte sensor |
US10524703B2 (en) | 2004-07-13 | 2020-01-07 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10722152B2 (en) | 2004-07-13 | 2020-07-28 | Dexcom, Inc. | Analyte sensor |
US10993641B2 (en) | 2004-07-13 | 2021-05-04 | Dexcom, Inc. | Analyte sensor |
US10799158B2 (en) | 2004-07-13 | 2020-10-13 | Dexcom, Inc. | Analyte sensor |
US10799159B2 (en) | 2004-07-13 | 2020-10-13 | Dexcom, Inc. | Analyte sensor |
US10980452B2 (en) | 2004-07-13 | 2021-04-20 | Dexcom, Inc. | Analyte sensor |
US10813576B2 (en) | 2004-07-13 | 2020-10-27 | Dexcom, Inc. | Analyte sensor |
US10827956B2 (en) | 2004-07-13 | 2020-11-10 | Dexcom, Inc. | Analyte sensor |
US10932700B2 (en) | 2004-07-13 | 2021-03-02 | Dexcom, Inc. | Analyte sensor |
US10918314B2 (en) | 2004-07-13 | 2021-02-16 | Dexcom, Inc. | Analyte sensor |
US10918313B2 (en) | 2004-07-13 | 2021-02-16 | Dexcom, Inc. | Analyte sensor |
US10617336B2 (en) | 2005-03-10 | 2020-04-14 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US11000213B2 (en) | 2005-03-10 | 2021-05-11 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10918317B2 (en) | 2005-03-10 | 2021-02-16 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10918318B2 (en) | 2005-03-10 | 2021-02-16 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10898114B2 (en) | 2005-03-10 | 2021-01-26 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10925524B2 (en) | 2005-03-10 | 2021-02-23 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10856787B2 (en) | 2005-03-10 | 2020-12-08 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10610137B2 (en) | 2005-03-10 | 2020-04-07 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10743801B2 (en) | 2005-03-10 | 2020-08-18 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10716498B2 (en) | 2005-03-10 | 2020-07-21 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10918316B2 (en) | 2005-03-10 | 2021-02-16 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10709364B2 (en) | 2005-03-10 | 2020-07-14 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10610135B2 (en) | 2005-03-10 | 2020-04-07 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US11051726B2 (en) | 2005-03-10 | 2021-07-06 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10610136B2 (en) | 2005-03-10 | 2020-04-07 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10813577B2 (en) | 2005-06-21 | 2020-10-27 | Dexcom, Inc. | Analyte sensor |
Also Published As
Publication number | Publication date |
---|---|
AU5088690A (en) | 1990-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Osserman et al. | Serum and urinary lysozyme (muramidase) in monocytic and monomyelocytic leukemia | |
Abramson et al. | The interaction between human monocytes and red cells: binding characteristics | |
US5196337A (en) | Human monoclonal antibody, and its production and use | |
Lancefield et al. | The properties of T antigens extracted from group A hemolytic streptococci | |
Valle et al. | Immune specific production of interferon by human T cells in combined macrophage-lymphocyte cultures in response to herpes simplex antigen | |
Roberts | The relationship between group A and group C meningococcal polysaccharides and serum opsonins in man | |
Rottini et al. | Identification and partial characterization of a cytolytic toxin produced by Gardnerella vaginalis | |
Gaines et al. | Prevalence of antibody to Pseudomonas in normal human sera | |
Taranta et al. | Dissociation of hemolytic and lymphocyte-transforming activities of streptolysin S preparations | |
Beachey et al. | Toxic effects of streptococcal M protein on platelets and polymorphonuclear leukocytes in human blood | |
Goodman et al. | Endotoxin protein is a mitogen and polyclonal activator of human B lymphocytes. | |
Cunningham et al. | Suppression of antibody response by group A streptococcal pyrogenic exotoxin and characterization of the cells involved | |
Wyler et al. | Response of sensitized and unsensitized human lymphocyte subpopulations to Plasmodium falciparum antigens | |
Kantor et al. | Preparation and antigenicity of M protein released from group A, type 1 streptococcal cell walls by phage-associated lysin | |
Halbert | THE USE OF PRECIPITIN ANALYSIS IN AGAR FOR THE STUDY OF HUMAN STREPTOCOCCAL INFECTIONS: III. THE PURIFICATION OF SOME OF THE ANTIGENS DETECTED BY THESE METHODS | |
Ogburn et al. | Extracellular antigens in steady-state cultures of the hemolytic streptococcus: production of proteinase at low pH | |
Dale et al. | Blastogenic responses of human lymphocytes to structurally defined polypeptide fragments of streptococcal M protein. | |
Bailey et al. | Antigenic properties of pleuropneumonia-like organisms from tissue cell cultures and the human genital area | |
WO1990007525A1 (en) | Keratoconjunctivitis cytotoxin and methods for its use and production | |
Mendes et al. | T and B lymphocytes in patients with lepromatous leprosy. | |
Janney et al. | Cold hemagglutinin cross-reactivity with Mycoplasma pneumoniae | |
Keiser et al. | “Nonspecific” stimulation of lymphocyte transformation by cellular fractions and acid extracts of group A streptococci | |
Barta et al. | Inhibition of lymphocyte blastogenesis by whey | |
Heilman et al. | TISSUE CULTURE STUDIES ON BACTERIAL ALLERGY IN EXPERIMENTAL BRUCELLOSIS: I. The Effect of Brucella suis Whole Antigen on Cultures of Spleen from Normal and Brucella-Infected Guinea Pigs | |
Rantz et al. | Antibacterial precipitating antibodies in group A hemolytic streptococcus sore throat |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CA CH DE DK FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB IT LU ML MR NL SE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |